M.L. Casalnuovo

Imlunestrant with or without Abemaciclib in Advanced Breast Cancer

Komal Jhaveri, Patrick Neven, M.L. Casalnuovo et al. · New England Journal of Medicine · 2024 · 109 citations

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Joseph Gligorov, Beyhan Ataseven, Mark Verrill et al. · European Journal of Cancer · 2017 · 46 citations

Breast Oncology, Medicine, Primary Analysis +7

Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09.

Sara M. Tolaney, Zefei Jiang, Qingyuan Zhang et al. · Journal of Clinical Oncology · 2025 · 23 citations

Abstract OT2-11-01: EMBER-3: A randomized phase 3 study of LY3484356, a novel, oral selective estrogen receptor degrader vs investigator’s choice of endocrine therapy of either fulvestrant or exemestane, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer previously treated with endocrine-based therapy

Komal Jhaveri, Nadia Harbeck, Philippe Aftimos et al. · Cancer Research · 2022 · 16 citations

Breast Oncology, Estrogen Receptor, Gynecology +20

Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer

Sara M. Tolaney, Zefei Jiang, Qingyuan Zhang et al. · New England Journal of Medicine · 2025 · 15 citations